The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Lupus: Clinical Trial Tracker

  • Lowest Price Guaranteed From USD 949

  • Published
    January 2017

  • Pages
    0

  • View Count
    1341

Example Insights

Available on request

Overview

Lupus is a serious, potentially fatal, autoimmune disease that attacks healthy tissue. The different types of the disease covered in the tracker include systemic lupus erythematosus (SLE), discoid lupus erythematosus (DLE), cutaneous lupus erythematosus (CLE), lupus nephritis and lupus vulgaris.

Several drugs, including anti-inflammatory drugs (aspirin and acetaminophen), non-steroidal anti-inflammatory drugs (NSAIDs) (ibuprofen, naproxen, indomethacin, nabumetone and celecoxib), corticosteroids (prednisone, prednisolone and methylprenisolone), antimalarials (chloroquine and hydroxychloroquine), immunosuppressive drugs (cyclophosphamide, methotrexate and azathioprine), and anticoagulants (low-dose aspirin, heparin and warfarin), are used for the treatment of the various symptoms associated with lupus. Benlysta®, co-developed by Human Genome Sciences and GSK, is the first and only drug to be specifically developed and approved for the treatment of lupus. Prior to Benlysta®’s approval in 2011, Plaquenil® (hydroxychloroquine) and corticosteroids, which were approved by the USFDA in 1955, were the only drugs available for lupus. Benlysta® is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of adult patients with active, autoantibody-positive SLE, who are receiving standard therapy

In addition to Benlysta®, H.P. Acthar® Gel (repository corticotropin injection) is approved by the USFDA for use during an exacerbation or as a maintenance therapy in selected cases of SLE. Cellcept® (mycophenolate mofetil), Mizoribine® (bredinin), and Prograf® (tacrolimus) are drugs approved for the treatment of lupus in Japan.

Amongst the therapies being developed for lupus, the trend is shifting from conventional small molecule drugs towards the development of biologics and novel treatment options, such as mesenchymal stem cells.

 

Scope of the Report

The primary objective of this report was to capture details on the various clinical trials that are currently underway in the field of lupus. We have identified a number of lupus drugs for various indications, including SLE, CLE, DLE, lupus nephritis and lupus vulgaris, and clinical trials that are either being conducted or are planned to be conducted for each of these drugs. For each specific product, we have provided the following information:

  1. Name of Primary Drug
  2. Mechanism of Action
  3. Indication (in highest phase of development)
  4. Highest Phase of Development
  5. Route of Administration (in highest phase of development)
  6. Originator
  7. Developer / Licensee
  8. Type of Developer

For each specific trial, wehave provided thefollowing information:

  1. Identity of Sponsor / Collaborator
  2. Type of Sponsor
  3. Trial Title
  4. Trial Objective
  5. Trial Phase
  6. Trial Status
  7. Start Date
  8. End Date
  9. Enrolment
  10. Age Group
  11. Age Range
  12. Inclusion Criteria
  13. Exclusion Criteria
  14. Allocation (Randomized / Non-Randomized)
  15. Masking (Single Blind / Double Blind / Open Label)
  16. Intervention Model (Parallel / Single Group / Crossover/ Factorial)
  17. Endpoint
  18. Primary Endpoint
  19. Secondary Endpoint
  20. Treatment Arms
  21. Route of Administration
  22. Trial Location
  23. Study Director
  24. Principle Investigator
  25. Primary Trial Identifier
  26. Other Identifiers
  27. Trial Results (if any)

The above information mentioned has been presented in the form a dashboard to provide a high level view of the ongoing activity in this space.

Contents

Introduction and Pipeline Details

  1. Market Overview
  2. Dashboard: Pipeline and Trial Analysis
  3. Clinical Development: Trial Details
  4. Preclinical Development
  5. Terminated Drugs
  6. Inclusion / Exclusion Criteria
  7. Abbreviations

List of Figures

Pipeline and Trial Details  
Figure 1  Lupus Overall Development Pipeline: Distribution by Stage of Development
Figure 2  Lupus Overall Development Pipeline: Distribution by Type of Indication
Figure 3  Lupus Overall Development Pipeline: Current Market Landscape
Figure 4  Lupus Clinical Development Pipeline: Distribution by Type of Indication
Figure 5  Lupus Clinical Development Pipeline: Distribution by Highest Phase of Development
Figure 6  Lupus Clinical Development Pipeline: Distribution by Route of Administration
Figure 7  Lupus Clinical Development Pipeline: Distribution by Type of Developer
Figure 8  Lupus Clinical Development Pipeline: Key Players
Figure 9  Lupus Clinical Trials: Distribution by Trial Status and Trial Phase
Figure 10 Lupus Clinical Trails: Distribution by Trial Phase
Figure 11 Lupus Clinical Trials: Distribution by Trial Status
Figure 12 Lupus Clinical Trials: Distribution by Type of Sponsor
Figure 13 Lupus Clinical Trials: Distribution by Allocation
Figure 14 Lupus Clinical Trials: Distribution by Masking
Figure 15 Lupus Clinical Trials: Distribution by Intervention Model
Figure 16 Lupus Clinical Trials: Distribution by Endpoint
Figure 17 Lupus Clinical Trials: Distribution by Route of Administration
Figure 18 Lupus Clinical Trials: Distribution by Location

List of Tables

Pipeline Details
Table 1 Lupus Clinical Development: Pipeline Details 
Table 2 Lupus Preclinical Development: Pipeline Details
Table 3 Lupus Terminated Drugs

Listed Companies

  1. Abbott
  2. AbbVie
  3. Ablynx
  4. Actelion
  5. Active Biotech
  6. Affiliated Hospital of Nanjing University Medical School
  7. Airmid
  8. Alliance for Children's Therapeutics (ACT)
  9. Amgen
  10. AnHui ShengLi Hospital
  11. Anthera Pharmaceuticals
  12. arGEN-X
  13. Argos Therapeutics
  14. Arkansas Heart Hospital
  15. Arthritis Research UK
  16. Asahi Kasei Pharma Corporation
  17. Aspreva Pharmaceuticals
  18. Assistance Publique - Hôpitaux de Paris
  19. Astellas Pharma
  20. Astion Pharma
  21. AstraZeneca
  22. Atlantic Bio Sci
  23. Aurinia Pharmaceuticals
  24. Autoimmunity Centers of Excellence
  25. Aventis Pharmaceuticals
  26. Baxalta
  27. Beijing Friendship Hospital
  28. Beijing ShuangLu Pharmaceutical
  29. Beike
  30. Berg
  31. Biogen
  32. Biotest
  33. Boehringer Ingelheim
  34. Bristol-Myers Squibb
  35. Buck Institute for Research On Aging
  36. Cambridge Antibody Technology
  37. Celgene
  38. Centocor
  39. Centre National de la Recherché Scientifique (CNRS)
  40. Cephalon
  41. Changhai Hospital
  42. Charite University, Berlin, Germany
  43. China Medical University
  44. Chinese University of Hong Kong
  45. Chong Kun Dang Pharmaceuticals
  46. Chugai Pharmaceuticals
  47. Chulalongkorn University
  48. Cipher Pharma
  49. Columbia University
  50. Corbus Pharmaceuticals
  51. CSL
  52. Cyteir Therapeutics
  53. CytoMed
  54. Daping Hospital, Third Military Medical University
  55. Delinia 
  56. Dutch Kidney Foundation
  57. Dutch Working Party on Systemic Lupus Erythematosus
  58. Dynavax Technologies
  59. Eli Lilly
  60. EMD Serono
  61. EMD Serono Research & Development Institute
  62. Emergent BioSolutions
  63. EULAR Lupus Nephritis Trial Network Study Group
  64. Euro Nippon Kayaku
  65. First Affiliated Hospital Bengbu Medical College
  66. First Affiliated Hospital of Wenzhou Medical University
  67. Fukuoka University Hospital
  68. Galapagos 
  69. Genelab Technologies
  70. Genentech
  71. Genfit
  72. Genosco
  73. Genovate Biotechnology
  74. Genovax
  75. Glycart Biotechnology 
  76. GSK
  77. Gunma University Graduate School of Medicine
  78. Guy's and St Thomas' NHS Foundation Trust
  79. HanAll Biopharma
  80. Hospital Authority, Hong Kong
  81. Huashan Hospital
  82. Human Genome Sciences
  83. ICON
  84. Idera Pharmaceuticals
  85. Iltoo Pharma
  86. Immune Tolerance Network (ITN)
  87. Immunomedics
  88. ImmuPharma
  89. Imperial College London
  90. Incyte Corporation
  91. Innovimmune
  92. INSERM
  93. Institute of Child Health, University College London, London, UK
  94. Invion
  95. Isotechnika
  96. Janssen
  97. Janssen-Cilag
  98. Japanese Study Group of Renal Disease in Children (JSRDC)
  99. Juntendo University
  100. Kadmon Pharmaceuticals
  101. Kagoshima University
  102. Karolinska Institutet
  103. Karyopharm Therapeutics
  104. Khon Kaen University
  105. KIMS Foundation and Research Center 
  106. King Chulalongkorn Memorial Hospital
  107. Kyorin Pharmaceutical 
  108. Kyushu University
  109. La Jolla Pharmaceutical Company
  110. Leiden University Medical Center
  111. Lonn Ryonn Pharma
  112. Maharaj Nakorn Chiang Mai Hospital
  113. Mallinckrodt
  114. Medarex
  115. Medical University of South Carolina
  116. MedImmune
  117. Medsenic Company
  118. Merck
  119. Ministry for Health and Solidarity, France
  120. Mitsubishi Tanabe Pharma
  121. Monash University
  122. Mount Tam Biotechnologies
  123. Nanjing Medical University
  124. Nantes University Hospital
  125. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  126. National Institutes of Health (NIH)
  127. National Institutes of Health Clinical Center (CC)
  128. National Natural Science Foundation of China
  129. Neovacs
  130. New York University School of Medicine
  131. Nimbus Therapeutics
  132. Northwell Health
  133. NovImmune
  134. Novo Nordisk
  135. Noxxon Pharma
  136. Ohio State University
  137. Okayama University Graduate School of Medicine
  138. Oklahoma Medical Research Foundation
  139. Omeros Corporation
  140. Organ Transplant Institute, China
  141. Oscotec
  142. Ospedale San Raffele
  143. Parexel
  144. Peking University People's Hospital
  145. Pfizer
  146. Pharmacyclics
  147. Plexxikon
  148. PPD
  149. PRA Health Sciences
  150. Principia Biopharma
  151. Qilu Hospital
  152. Ra Pharmaceuticals
  153. Rajavithi Hospital
  154. Ramathibodi Hospital 
  155. RedHill Biopharma
  156. Rediscovery Life Sciences
  157. Redx Pharma
  158. RemeGen
  159. RenJi Hospital
  160. Resolve Therapeutics
  161. Rigel Pharmaceuticals
  162. Roche
  163. Ruijin Hospital
  164. Saitama Medical University
  165. Sanofi
  166. SBI Biotech
  167. Seattle Genetics
  168. Second Affiliated Hospital, School of Medicine, Zhejiang University
  169. Seoul National University Hospital
  170. Shanghai 10th People's Hospital, Shanghai Zhongshan Hospital
  171. Shanghai General Hospital
  172. Shanghai Jiao Tong University School of Medicine
  173. Shire
  174. Sidney Kimmel Comprehensive Cancer Center
  175. SinoMab Bioscience
  176. Siriraj Hospital
  177. Songklanagarind Hospital
  178. Spherium Biomed
  179. Srinagarind Hospital
  180. Sun Yat-sen University
  181. SuppreMol
  182. Syntimmune
  183. Takeda Pharmaceutical
  184. Targazyme
  185. TetraGenetics
  186. Teva Pharmaceutical
  187. The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
  188. The First Affiliated Hospital of Anhui Medical University
  189. The First Affiliated Hospital of Soochow University
  190. The First Affiliated Hospital with Nanjing Medical University
  191. The Kidney Foundation, Japan 
  192. The Medical University of South Carolina
  193. TheraMAB
  194. Tiziana Life Sciences
  195. Toho University School of Medicine
  196. Tohoku University Hospital
  197. Tokyo Medicine and Dental University
  198. Tokyo Metropolitan Children's Hospital 
  199. Toyoma Chemical
  200. Tuen Mun Hospital
  201. TxCell
  202. UCB Pharma
  203. United States Department of Defense
  204. Université Catholique de Louvain
  205. University Hospital Muenster
  206. University Hospital, Bordeaux 
  207. University of California at Irvine
  208. University of California, Los Angeles
  209. University of Leeds
  210. University of Massachusetts
  211. University of Tsukuba
  212. UPMC - University Pierre and Marie CURIE
  213. Vaccinex
  214. viDA Therapeutics
  215. Wake Forest School of Medicine
  216. Walter and Eliza Hall Institute of Medical Research
  217. Washington University
  218. Weizmann Institute of Science
  219. West China Hospital
  220. Wyeth
  221. Xencor
  222. XTLbio
  223. Yantai RC-Pharmaceutical
  224. Zhejiang University
  225. ZonMw: The Netherlands Organisation for Health Research and Development
  226. ZymoGenetics

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 949

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com